chromosome 12p13.2. Mucosal bleeding is typical of all VWD cases. Here, we describe a VWF gene mutation that has not been previously reported in the literature. A 67-year-old post-menopausal Caucasian female with history of menorrhagia and osteoarthritis presented with scratch purpura and ecchymosis on both arms. She denied epistaxis or any recent major bleeding, but was taking aspirin and naproxen. Family history was significant for occasional epistaxis in her two sisters and her daughter. All her initial blood work, including coagulation and complement factors, were normal. However, VWF gene analysis detected a novel polymorphism in one copy of the c. 1280T>C (p. Ile427Thr) variant on exon 11. This novel polymorphism has not, to the best of our knowledge, been previously reported in the literature. This case illustrates a new and unique heterozygous variant of VWF gene polymorphism presenting with a mild increased incidence of bleeding. We are unable to determine if this is inherited or sporadic since the family refused testing. This condition could predict the possibility of serious bleeding in the event of major surgery or trauma. We do not know what would be the risk of using longterm antiplatelet agents in this patient.
INTRODUCTION
VWF is a multimeric multidomain adhesive protein that plays an important role in primary hemostasis by promoting platelet adhesion to the subendothelium at sites of vascular injury and platelet-platelet interactions in high shear-rate conditions. It is also the carrier of factor VIII (FVIII), and thus indirectly contributes to the coagulation process. [1] Molecular biology techniques have been used to map the VWF gene. The VWF gene is highly polymorphic and a number of single nucleotide polymorphisms have been found that contribute to large variation in "normal" VWF levels.
VWD is a bleeding disorder caused by a dysfunctional VWF and is the most common inherited disorder of the coagulation proteins in humans. VWD has a prevalence of about 1% in the general population, but the true incidence of clinically relevant cases is lower (about 100/million inhabitants). Bleeding manifestations are heterogeneous; and mucosal bleeding is typical of all VWD cases, but hemarthrosis and hematomas may also be present when FVIII levels are low. [2] Patients with VWD can become symptomatic at any age.
VWD is associated with mutations on chromosome 12 in the p13.2 region that encode VWF, which is synthesized in endothelial cells and megakaryocytes. [3] It is either inherited as an autosomal dominant trait or acquired due to several different pathophysiological mechanisms. An array of tests is usually required to characterize VWD type and to establish the best treatment modality.
CASE DESCRIPTION (MATERIALS/METHODS)
A 67-year-old post-menopausal Caucasian female was referred to the MountainView Hospital Division of Hematology and Oncology for evaluation of persistent purpuric lesions on both arms. Her medical history was significant for knee osteoarthritis and menorrhagia during her reproductive years. Her home medications were multivitamins, baby aspirin and naproxen for pain as needed. She denied recent trauma or any other bleeding. She was a current daily smoker. Family history was significant for occasional epistaxis in both of her sisters and her daughter. On physical examination scratch purpura and multiple old and new non blanching ecchymoses of variable size were seen on both arms.
The patient was evaluated for persistant ecchymoses that was out of proportion to her aspirin and nonsteroidal anti-inflammatory drug (NSAID) use. Complete blood count (CBC), coagulation profile, serum and urine protein electrophoresis, iron studies, total complement (CH 50), serum beta-2 microglobulin, concentration of VWF antigen (VWF: Ag), Ristocetin induced platelet agglutination (RIPA) and ANA were normal. However, VWF gene analysis detected a novel polymorphism in one copy of a c. 1280T>C (p. Ile427Thr) variant in exon 11 which has not been previously reported in the literature. Her aspirin and naproxen were stopped. During a follow-up visit, the patient reported spontaneous resolution of her lesions. She was also found to have diffuse atherosclerosis in the abdominal aorta with greater than 50% hemodynamically-significant stenosis of the proximal right common iliac
artery. Of note, her total cholesterol was 183 mg/dl, LDL 73 mg/dl and triglyerides were 275 mg/dl. Her blood pressure throughout her office visits was between 110/70 mmHg to 147/93 mmHg. She is being evaluated by her cardiologist for long-term antiplatelet therapy. She was counseled about getting her siblings and children tested for the same polymorphism, but two sisters declined testing, while the daughter who agreed was awaiting for approval from her insurance carrier. The patient has been lost to followup for the last couple of months.
DISCUSSION
VWD was first described by Erik von Willebrand in a Scandinavian family in 1923. [4] There are three major subtypes of VWD. These are classified as: a partial quantitative deficiency of VWF (type 1 VWD) with variable bleeding tendency; a qualitative deficiency (type 2 VWD) with more homogeneous dysfunctional VWF; or virtually complete deficiency (type 3 VWD). Type 1 and type 2 VWD have an autosomal dominant pattern of inheritance, while type 3 is inherited as a recessive trait. The diagnosis of VWD, especially type 1, is difficult since the laboratory phenotype is highly heterogenous and is compounded by factors outside the VWF gene (including age, race, blood group specially blood group O, pregnancy, stress, hormones and smoking) that influence VWF levels. Diagnosis is usually made by reviewing the patient's personal and family history of bleeding and by clinical evaluation for more common reasons for bleeding, which is then supplemented with laboratory tests. Assessment may be used to determine bleeding risk before surgery and other invasive procedures, and to diagnose reasons for unexplained bleeding. [5] Acquired forms of WVD are most frequently described in patients with clonal lymphoproliferative and autoimmune diseases (e.g., systemic lupus erythromatosis). Nonimmune mechanisms that have been described include adsorption of VWF onto tumor cells (Wilms' tumor, multiple myeloma and Waldenstrom's macroglobulinemia), VWF multimers degradation (decompensated cirrhosis, pancreatitis, myeloproliferative disorders and disseminated intravascular coagulation) and reduced levels in heart diseases (noncyanotic congenital heart diseases and high-grade aortic stenosis).
VWF is a large multimeric and multidomain glycoprotein that mediates the attachment of platelets to damaged endothelium and also serves as the carrier protein for coagulation factor VIII (FVIII), protecting it from proteolytic degradation. [6] It circulates in plasma at a concentration of 0.5-1.0 mg/dl; 15% of which is contained within the platelets. Larger VWF multimers (as high as 10,000-20,000 kDa) are targeted to endothelial cytoplasmic storage granules, the Wiebel-Palade bodies. [7] In platelets, VWF is stored in a-granules. [8] VWF is synthesized by endothelial cells and megakaryocytes. Synthesis of VWF is regulated in part by hormones because VWF production in endothelial cells is increased by estrogen and thyroid hormones. [9, 10] The gene coding for VWF has been cloned and located at chromosome 12p13.2. It is a large gene composed of about 178 kilobases and contains 52 exons. There is also a noncoding pseudogene located in chromosome 22. [11] .
These multiple domains deliver the unique hemostatic abilities of VWF, including the localization of plateletbinding sites in the A1, C1, and C2 domains, collagen binding in the A1 and A3 domains, and a FVIII-binding site in the D', D3 domains. The high-molecular-weight multimers are the most effective forms of VWF that mediate platelet adhesion at sites of vascular injury.
The VWF gene polymoprphism that we are reporting is located on exon 11, corresponding to domain D2. Amplification was done for more common splice junction sites on selected exons (exons 11, 12, 14, 15, 16, 18, 19, 20 , 24, 27 and 52). This does not include any comprehensive evolution for other less frequent variations that may be detected using mRNA splicing and protein synthesis. At this time we are unsure of the underlying pathogenetic mechanisms leading to this polymorphism. The cleavage of ultra-large-molecular-weight multimers leads to the production of smaller, lower-molecular-weight multimers that are inherently less hemostatically active. [11] Although low laboratory values are common in VWD patients, only a fraction of such patients seek medical attention due to bleeding symptoms. The low incidence of bleeding is due to the mild nature of the disease in many patients and due to the lack of bleeding challenges and/or lack of recognition of excessive bleeding (e.g., heavy menstrual bleeding) in others. In addition, the highly heterogeneous phenotype and presence of factors outside the VWF gene make diagnosis of VWD difficult and is almost always delayed, which could have been the case in our patient. the diagnostic testing should be repeated on two or more occasions separated by 4-6 weeks, as was done with our patient. There is no single straightforward diagnostic test available to either confirm or exclude the diagnosis. Newer assays of VWF function are becoming more available and are useful in determining the laboratory diagnosis of VWD. [12] VWF is synthesized with a very large propeptide (VWFpp) that is critical for the intracellular processing of VWF through dimerization and multimerization for optimal functioning. We believe that the gene polymorphism we are reporting here might perhaps lead to a hypoproduction of protein product. The routine use of aspirin and NSAID may have unmasked this prior undetected gene polymoprphism, which then became clinically apparent. This variant has not been reported earlier in the VWF database. [13] Our patient also had peripheral arterial disease with hemodynamically significant stenosis. Due to her current bleeding, aspirin was stopped. At this point we are uncertain about the risks and benefits of starting antiplatelets or anti-coagulants in this patient. A review of data did not show any studies done to date on the safety of longterm antiplatelet therapy in patients of VWD and peripheral arterial disease, with the exception of acute coronary syndromes where patients underwent percutaneous coronary intervention with adjuvant antiplatelet and antithrombotic therapy for short periods without significant bleeding complications [14, 15] 
RESULTS/CONCLUSION
This case illustrates a new and unique heterozygous variant of VWF gene polymophism presenting with a mild increased incidence of bleeding. Recent advances have illuminated the ways in which VWF contributes to both kinds of hemostatic emergency, whether minor or major life threating, often through disturbances in VWF synthesis or catabolism.
It is essential to conduct a future comprehensive study, including clinical, basic, and special testing, laboratory tests, in order to establish a correct diagnosis, develop new therapeutic approaches, and offer appropriate medical care and genetic counselling to our patients.
It is possible to determine if this is inherited or sporadic by testing family members for the same gene mutation, which could predict the possibility of serious bleeding in the event of a major surgery or trauma. For now, we do not know what the risk would be of using long-term antiplatelet agents for vascular stenosis in these patients.
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